These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4053238)

  • 1. Spectrofluorometric determination of FUT-175 (nafamstat mesilate) in blood based on trypsin-inhibitory activity.
    Aoyama T; Sasaki H; Shibuya M; Suzuki Y
    Chem Pharm Bull (Tokyo); 1985 May; 33(5):2142-4. PubMed ID: 4053238
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
    Aoyama T; Ino Y; Ozeki M; Oda M; Sato T; Koshiyama Y; Suzuki S; Fujita M
    Jpn J Pharmacol; 1984 Jul; 35(3):203-27. PubMed ID: 6482087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis].
    Iwaki M; Ozeki M; Sato T; Suzuki K; Motoyoshi A; Suzuki S; Fujita M; Aoyama T
    Nihon Yakurigaku Zasshi; 1984 Oct; 84(4):363-72. PubMed ID: 6210233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis.
    Gabryelewicz A; Prokopowicz J; Bodzenta A; Bielecki W; Rydzewska G
    Digestion; 1988; 40(1):19-24. PubMed ID: 3234615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological studies of FUT-175, nafamstat mesilate. III. Anti-inflammatory activities of FUT-175].
    Iwaki M; Oda M; Ozeki M; Ino Y; Suzuki K; Koshiyama Y; Motoyoshi A; Ogihara M; Suzuki S; Fujita M
    Nihon Yakurigaku Zasshi; 1984 Oct; 84(4):373-84. PubMed ID: 6239813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of HPLC measurement of plasma concentration of gabexate mesilate.
    Nishijima MK; Takezawa J; Taenaka N; Shimada Y; Yoshiya I
    Thromb Res; 1983 Jul; 31(2):279-84. PubMed ID: 6415853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight proteinase inhibitor in human plasma inhibiting papain and trypsin activity.
    Takiuchi I; Sei Y; Takagi H; Sagawa Y
    Experientia; 1984 Aug; 40(8):846-7. PubMed ID: 6468596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis].
    Koshiyama Y; Ozeki M; Motoyoshi A; Fujita M; Iwaki M; Aoyama T
    Nihon Yakurigaku Zasshi; 1984 Nov; 84(5):417-28. PubMed ID: 6519580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood antiprotease activity and alpha-1-protease inhibitor level in patients with myocardial infarct].
    Orlov VN; Solod NN; Iunusov MA; Radzevich AE
    Kardiologiia; 1990 May; 30(5):64-6. PubMed ID: 2391814
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary structure of a proteinase inhibitor released from goat serum inter-alpha-trypsin inhibitor.
    Rasp G; Hochstrasser K; Gerl C; Wachter E
    Biochim Biophys Acta; 1989 Dec; 999(3):335-7. PubMed ID: 2481505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafamstat mesilate attenuates pulmonary hypertension in heparin-protamine reactions.
    Kreil E; Montalescot G; Greene E; Fitzgibbon C; Robinson D; Chenoweth D; Zapol WM
    J Appl Physiol (1985); 1989 Oct; 67(4):1463-71. PubMed ID: 2793750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proteolytic enzyme inhibitors and the antitryptic blood serum capacitance in acute suppurative peritonitis].
    Protsenko AV; Starosek VN
    Klin Khir (1962); 1984 Jun; (6):60-1. PubMed ID: 6471711
    [No Abstract]   [Full Text] [Related]  

  • 15. [Age-related characteristics of the content of the basic enzyme inhibitors of proteolysis and of the indices of antitryptic capacity in the blood serum].
    Bogadel'nikov IV; Protsenko AV
    Pediatriia; 1983 May; (5):12-3. PubMed ID: 6877934
    [No Abstract]   [Full Text] [Related]  

  • 16. [Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1237-43. PubMed ID: 11579633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum protease inhibitors in jaundice.
    Aroor AR; Pattabiraman TN
    Indian J Exp Biol; 1979 May; 17(5):503-6. PubMed ID: 521065
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum protease inhibitors in EPH-gestosis].
    Warwas M; Malinowski J; Sward J
    Wiad Lek; 1983 Sep; 36(18):1519-22. PubMed ID: 6666132
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigation of inter-alpha-trypsin inhibitor and slow migrating proteinase inhibitors in serum and urine.
    Odum L
    Dan Med Bull; 1991 Feb; 38(1):68-77. PubMed ID: 1709082
    [No Abstract]   [Full Text] [Related]  

  • 20. [Contrapsin, a novel trypsin inhibitor in the mouse plasma].
    Takahara H; Sinohara H
    Seikagaku; 1983 Dec; 55(12):1426-33. PubMed ID: 6609216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.